Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovar...(glutathione analog for the treatment of ...),Health

Date:5/31/2009

glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat ovarian cancer, the effectiveness of TELCYTA in combination with PLD and in patients under certain platinum refractory and platinum resistant conditions, and the effectiveness of TELCYTA upon stomatitis and PPE associated with PLD. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2009. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

'/>"/>

SOURCE Telik, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. Telik Announces Preclinical Presentations at AACR Annual Meeting
2. Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance
3. Telik Announces Year-End Financial Release, Conference Call and Webcast
4. Telik Announces Patents on Compounds Related to TELINTRA
5. Telik Announces Preclinical Presentations at AACR Annual Meeting
6. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
7. Lumenis(R) Presents the SlimLine(TM) GI Laser Fiber: The Latest Advancement in Laser Lithotripsy for Gastroenterology
8. Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook
9. AGA Institute presents cutting-edge research during DDW
10. The Pediatric IBD Center at Cedars-Sinai Medical Center Presents Rock-n-Reel 2009 Honoring Alexandra Milchan-Lambert & Scott Lambert
11. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting